Navidea Biopharma (NAVB) Shares Tick Higher on Positive CHMP Opinion for Lymphoseek

September 16, 2016 8:20 AM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Navidea Biopharma (NYSE: NAVB) shares are markedly higher amid a positive CHMP opinion on Lymphoseek issued this week. The stock is up nearly 9 percent in premarket trading.

For more color, click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Add Your Comment